Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, at the 2017 Annual American Academy of Dermatology (AAD) Meeting taking place March 3-7 in Orlando, FL.

"Not all people with psoriasis respond to currently available therapies or are able to maintain long-term symptom control. We are looking forward to sharing new and continued insights about tildrakizumab at AAD and upcoming meetings," said Jesper Jensen, Executive Vice President, Biologics and Dermatology, Sun Pharma. "With origins in dermatology that stretch back more than 30 years, we are committed to patients suffering from skin conditions. At Sun Dermatology, we care to make a difference."

Tildrakizumab data analyses being presented at AAD include:

• Tildrakizumab, a Selective Anti-IL-23 Monoclonal Antibody, Is Effective in Subjects With Chronic Plaque Psoriasis Who Do Not Adequately Respond to Etanercept – Poster 5252 (Pearls of the Symposium Session on Friday, March 3^rd from 2:30 PM to 2:40 PM)
• Efficacy of Tildrakizumab, an Anti-IL23p19 Monoclonal Antibody, Stratified by Prior Exposure to Biologics in a Randomized, Placebo-Controlled Phase 3 Clinical Trial – Poster 5111 (Psoriasis & Other Papulosquamous Disorders Section on Sunday, March 5^th from 9:20 AM to 9:25 AM)
• Maintenance of Treatment Response in Chronic Plaque Psoriasis Patients Continuing Treatment or Discontinuing Treatment With Tildrakizumab in a 64-Week, Randomized Controlled, Phase 3 Trial – Poster 4855 (Psoriasis & Other Papulosquamous Disorders Section onSunday, March 5^th from 11:35 AM to 11:40 AM)
• The Effect of Tildrakizumab, a High-Affinity, Selective Anti-IL23p19 Monoclonal Antibody, on Cytochrome P450 Metabolism – Poster 4792 (Pharmacology Section on Sunday, March 5^th from 12:55 PM to 1:00 PM)

More than 1,800 patients across more than 200 clinical sites participated in the tildrakizumab Phase-3 pivotal trials (reSURFACE 1 and 2). Data were presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016. Regulatory filings for tildrakizumab in the US and Europe are proceeding as planned.